Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib for MRD in HR+/HER2- Early Breast Cancer
NCT07292207Phase 2Not yet recruiting
- Sponsor
- Nagoya City University
- Start
- Jan 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in breast cancer, sponsored by Nagoya City University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07292207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292207.